Where Neurocrine Biosciences Stands With Analysts
Portfolio Pulse from Benzinga Insights
Neurocrine Biosciences (NASDAQ:NBIX) has received mixed analyst ratings over the last three months, with a shift towards more bullish sentiment. The average 12-month price target is $153.78, marking an 8.39% increase from the previous target. Analyst actions include both upgrades and downgrades, reflecting responses to market conditions and company performance. Neurocrine Biosciences, a pharmaceutical company, has shown a solid revenue growth rate of 25.05% as of December 31, 2023, but faces challenges in profitability and efficiency metrics compared to industry averages.
April 10, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neurocrine Biosciences has seen a shift towards more bullish sentiment among analysts, with an updated average 12-month price target of $153.78. The company reported a revenue growth of 25.05% but struggles with profitability and efficiency.
The increase in the average 12-month price target and the shift towards more bullish sentiment among analysts suggest a positive short-term impact on NBIX's stock price. However, the company's challenges in profitability and efficiency metrics could temper gains.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100